A large, 19-year, population-based prospective follow-up study in 491 hypertensive and 513 control subjects (cardiovascular disease incidence was a parallel outcome of the study) found that baseline plasma ghrelin level had no association with cancer deaths or hospital events in either cohort (Laurila et al. 2014). This evidence concerns the gene GHRL and cancer.